ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (AMEX:ISV) today announced preliminary results from the company’s Phase 3a clinical trial of ISV-502 (AzaSite Plus™) a topical combination antibiotic/corticosteroid product for the treatment of blepharoconjunctivitis. Blepharoconjunctivitis, also known as lid margin disease, is a chronic inflammatory disease of the inside and outside of the eyelid with no approved treatment. ISV-502 improved clinical outcomes as compared to treatment with a corticosteroid alone or antibiotic alone in the reduction of inflammatory signs and symptoms and bacterial eradication, respectively. In addition, ISV-502 was very well tolerated. However, an initial evaluation of the data indicates that the trial did not achieve its primary endpoint as defined by the protocol.
